Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Horizon Therapeutics Llc patents


Recent patent applications related to Horizon Therapeutics Llc. Horizon Therapeutics Llc is listed as an Agent/Assignee. Note: Horizon Therapeutics Llc may have other listings under different names/spellings. We're not affiliated with Horizon Therapeutics Llc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "H" | Horizon Therapeutics Llc-related inventors


Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of phenylacetic acid prodrugs

The present disclosure provides methods for adjusting the dosage of paa prodrugs (e.g., hpn-100, pba) based on measurement of paa and pagn in plasma and calculating the paa:pagn ratio so as to determine whether paa to pagn conversion is saturated.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of treating urea cycle disorders

The present disclosure provides novel methods for determining an effective dosage of a paa prodrug and for treating a ucd that incorporate body surface area and urinary pagn concentration. The disclosure further provides novel methods for assessing compliance with paa prodrug administration that incorporate urinary pagn concentration, and the subject's current dosing regimen, bsa, or age. ... Horizon Therapeutics Llc

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy

The present disclosure provides methods for treating hepatic encephalopathy (he) and for optimizing and adjusting nitrogen scavenging drug dosage for subjects with he.. . ... Horizon Therapeutics Llc

Methods of treating urea cycle disorders

The present disclosure provides novel methods for determining an effective dosage of a paa prodrug and for treating a ucd that incorporate body surface area and urinary pagn concentration. The disclosure further provides novel methods for assessing compliance with paa prodrug administration that incorporate urinary pagn concentration, and the subject's current dosing regimen, bsa, or age. ... Horizon Therapeutics Llc

01/18/18 / #20180015064

Methods of therapeutic monitoring of nitrogen scavenging drugs

The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.. . ... Horizon Therapeutics Llc

01/18/18 / #20180015058

Methods of therapeutic monitoring of phenylacetic acid prodrugs

The present disclosure provides methods for adjusting the dosage of paa prodrugs (e.g., hpn-100, pba) based on measurement of paa and pagn in plasma and calculating the paa:pagn ratio so as to determine whether paa to pagn conversion is saturated.. . ... Horizon Therapeutics Llc

12/21/17 / #20170362160

Procedure for the preparation of 4-phenyl butyrate and uses thereof

Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.. ... Horizon Therapeutics Llc

12/14/17 / #20170354632

Methods of treating urea cycle disorders

The present disclosure provides novel methods for determining an effective dosage of a paa prodrug and for treating a ucd that incorporate body surface area and urinary pagn concentration. The disclosure further provides novel methods for assessing compliance with paa prodrug administration that incorporate urinary pagn concentration, and the subject's current dosing regimen, bsa, or age. ... Horizon Therapeutics Llc

12/14/17 / #20170354631

Methods of treating urea cycle disorders

The present disclosure provides novel methods for determining an effective dosage of a paa prodrug and for treating a ucd that incorporate body surface area and urinary pagn concentration. The disclosure further provides novel methods for assessing compliance with paa prodrug administration that incorporate urinary pagn concentration, and the subject's current dosing regimen, bsa, or age. ... Horizon Therapeutics Llc

12/07/17 / #20170348269

Treatment of urea cycle disorders in neonates and infants

Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-pagn and plasma paa:pagn ratio.. . ... Horizon Therapeutics Llc

11/30/17 / #20170342018

Procedure for the preparation of 4-phenyl butyrate and uses thereof

Provided is a process for preparing 4-phenyl-1-butyric acid, comprising: reacting 4-phenyl-1-butanol with sodium chlorite, a nitroxyl radical catalyst and sodium hypochlorite in an organic solvent and a phosphate buffer; and quenching the reaction with sodium sulfite to produce 4-phenyl-1-butyric. Also provided is 4-phenyl-1-butyric acid prepared by such a process.. ... Horizon Therapeutics Llc

09/21/17 / #20170266143

Methods of therapeutic monitoring of phenylacetic acid prodrugs

The present disclosure provides methods for adjusting the dosage of paa prodrugs (e.g., hpn-100, pba) based on measurement of paa and pagn in plasma and calculating the paa:pagn ratio so as to determine whether paa to pagn conversion is saturated.. . ... Horizon Therapeutics Llc

03/30/17 / #20170087113

Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels

The present disclosure provides methods for preventing hyperammonemia crises (hacs) in subjects with a urea cycle disorder (ucd) and for optimizing and adjusting nitrogen scavenging drug dosage for subjects with ucds to prevent hacs.. . ... Horizon Therapeutics Llc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Horizon Therapeutics Llc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Horizon Therapeutics Llc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###